Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Type:
Grant
Filed:
August 17, 2020
Date of Patent:
May 28, 2024
Assignee:
KOTA BIOTHERAPEUTICS, LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Type:
Application
Filed:
August 17, 2020
Publication date:
April 1, 2021
Applicant:
KOTA BIOTHERAPEUTICS, LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Type:
Grant
Filed:
March 19, 2018
Date of Patent:
August 18, 2020
Assignee:
Kota Biotherapeutics, LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Type:
Grant
Filed:
July 26, 2019
Date of Patent:
March 24, 2020
Assignee:
Kota Biotherapeutics, LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight